tRF ‐34‐ P4R8YP9LON4VHM Promotes Hepatocellular Carcinoma Progression and Tumour Cell‐Induced Angiogenesis via the MEK / ERK Pathway
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Tianxin Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neovascularization, Pathologic, MAP Kinase Signaling System. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Postgraduate Research & Practice Innovation Program of Jiangsu Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and poses a significant global health challenge. In recent years, tRNA‐derived small RNAs (tsRNAs) have gained significant attention due to their potential role in various cancers, including HCC. In this study, we reported that tRF‐34‐P4R8YP9LON4VHM expression was elevated in HCC tissues and cell lines. The association between tRF‐34‐P4R8YP9LON4VHM expression and HCC patients' clinicopathological parameters was determined using tissue microarrays of 90 patients, and we found that it was positively associated with the level of AFP, tumour size, microvascular density (MVD), and TNM stage. We performed CCK8, colony formation assay, EdU, cell cycle analysis, transwell assay, and tube formation assay to verify that tRF‐34‐P4R8YP9LON4VHM could enhance HCC proliferation, migration, invasion, and tumour cell‐induced angiogenesis in vitro and in vivo. Mechanistically, tRF‐34‐P4R8YP9LON4VHM could downregulate DAB2IP expression by directly targeting its 3'‐UTR, consequently activating the MEK/ERK signalling pathway and promoting the secretion of VEGFA from HCC cells into the supernatant. In conclusion, our research indicated that tRF‐34‐P4R8YP9LON4VHM might act as a crucial player in molecular mechanisms and provide novel treatment strategies for HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
- Department of Anesthesiology and Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
ORCID-Profile: Zhong Chen
Förderung
- National Natural Science Foundation of China
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
Zitieren
APA
Xu, T., Hua, H., Song, F., Zhang, N., Gao, C., & Chen, Z. (2025). tRF ‐34‐ P4R8YP9LON4VHM Promotes Hepatocellular Carcinoma Progression and Tumour Cell‐Induced Angiogenesis via the MEK / ERK Pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70560
Vancouver
Xu T, Hua H, Song F, Zhang N, Gao C, Chen Z. tRF ‐34‐ P4R8YP9LON4VHM Promotes Hepatocellular Carcinoma Progression and Tumour Cell‐Induced Angiogenesis via the MEK / ERK Pathway. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70560
BibTeX
@article{Xu2025,
author = {Xu, Tianxin and Hua, Han and Song, Fei and Zhang, Nannan and Gao, Cheng and Chen, Zhong},
title = {tRF ‐34‐ P4R8YP9LON4VHM Promotes Hepatocellular Carcinoma Progression and Tumour Cell‐Induced Angiogenesis via the MEK / ERK Pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70560}
}
EUVIMED